A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants (NCT06663332)
CNTO1959ISD3001: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
Who can join: Review the eligibility criteria below.
Location: Emory University — Atlanta, Georgia
Age range: 3 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (49 Sites)
Showing the first 25 of 49 sites.
- Emory University — Atlanta, Georgia
- Children's Center for Digestive Healthcare — Atlanta, Georgia
- Riley Hospital for Children — Indianapolis, Indiana
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- University of Utah — Salt Lake City, Utah
- Instituto Caici — Rosario,
- The Kids Research Institute Australia on behalf of the Centre for Child Health Research — Nedlands,
- Mater Hospital Brisbane Inflammatory Bowel Diseases — South Brisbane,
- The Children's Hospital at Westmead — Westmead,
- Hospital das Clinicas - UFG — Goiânia,
- INTEGRAL Pesquisa e Ensino — Votuporanga,
- Capital Center For Children's health Capital Medical University — Beijing,
- Changzhou No 2 Peoples Hospital — Changzhou,
- The Childrens Hospital Zhejiang University School Of Medicine — Hangzhou,
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine — Hangzhou,
- Ruijin Hospital Shanghai Jiao Tong University — Shanghai,
- Shengjing Hospital Of China Medical University — Shenyang,
- Hospital Center University De Lille — Lille,
- Schon Klinik Hamburg Eilbek — Hamburg,
- Asklepios Klinik Sankt Augustin — Sankt Augustin,
- ASST Papa Giovanni XXIII Bergamo — Bergamo,
- Azienda USL di Bologna - Ospedale Maggiore — Bologna,
- IRCCS Ospedale Pediatrico Bambino Gesu — Roma,
- Casa Sollievo Della Sofferenza IRCCS — San Giovanni Rotondo,
- IRCCS Materno Infantile Burlo Garofolo — Trieste,
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Crohns Disease
- Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease — Dothan, Alabama
- Oral N-acetylglucosamine in Crohn's Disease — Baltimore, Maryland
- Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation — New York, New York
- Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD — Hamilton, Ontario
- Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy — Rochester, Minnesota
Explore by condition: All Crohns Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.